Securing wider EU commitment to the elimination of hepatitis C virus
暂无分享,去创建一个
M. Poljak | M. Buti | J. Lazarus | R. Marinho | A. Hatzakis | H. Razavi | S. Pol | Z. Younossi | H. Wedemeyer | S. Hutchinson | G. Esmat | R. Esteban | L. Castéra | A. Aghemo | V. Sypsa | P. Bruggmann | M. Maticic | D. Goldberg | G. Papatheodoridis | N. Tözün | M. Carballo | M. Colombo | Yuval Dadon | L. Kondili | H. Janssen | R. Baptista-Leite | M. Peck‐Radosavljevic | J. Lambert | C. Buşoi | T. Tergast | Cora Pop | Joan Colom Farran | G. Kalamitsis | M. Bartoli | Kostas Bakoyannis | Rodrigo Sousa Coutinho | Mark Gillyon-Powell | Aldo Patricello | Tomislov Sokol | Ricardo Baptista-Leite
[1] M. Persico,et al. Hepatitis C screening during SARS‐CoV‐2 testing or vaccination. Experience in an area of southern Italy in the province of Salerno , 2022, Liver international : official journal of the International Association for the Study of the Liver.
[2] F. Tacke,et al. Updated epidemiology of hepatitis C virus infections and implications for hepatitis C virus elimination in Germany , 2022, Journal of viral hepatitis.
[3] P. Lampertico,et al. Implementation of HCV screening in the 1969–1989 birth‐cohort undergoing COVID‐19 vaccination , 2022, Liver international : official journal of the International Association for the Study of the Liver.
[4] Jisoo A. Kwon,et al. Global change in hepatitis C virus prevalence and cascade of care between 2015 and 2020: a modelling study. , 2022, The lancet. Gastroenterology & hepatology.
[5] B. Maasoumy,et al. Glecaprevir/Pibrentasvir + Sofosbuvir + Ribavirin als Reserveregime nach Sofosbuvir + Velpatasvir + Voxilaprevir Re-Therapieversagen , 2021, Zeitschrift für Gastroenterologie.
[6] J. Lazarus,et al. Effectiveness of a screening program for HBV, HCV, and HIV infections in African migrants to Sicily. , 2021, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.
[7] P. Hayes,et al. Population-level estimates of hepatitis C reinfection post scale-up of direct-acting antivirals among people who inject drugs , 2021, Journal of hepatology.
[8] F. Ponziani,et al. Management of liver disease in Italy after one year of the SARS‐CoV‐2 pandemic: A web‐based survey , 2021, Liver international : official journal of the International Association for the Study of the Liver.
[9] V. Frochot,et al. Intravenous ketamine is a risk factor for jaundice in Covid-19 patients , 2021, Journal of Hepatology.
[10] H. Wedemeyer,et al. Reaching the Unreachable: Strategies for HCV Eradication in Patients With Refractory Opioid Addiction—A Real-world Experience , 2021, Open forum infectious diseases.
[11] M. Andreoni,et al. Milestones to reach Hepatitis C Virus (HCV) elimination in Italy: From free-of-charge screening to regional roadmaps for an HCV-free nation. , 2021, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.
[12] M. Persico,et al. Associated screening for HCV and SARS-Cov2 infection in an urban area of Southern Italy: the “Casola di Napoli” cohort study , 2021, Digestive and Liver Disease.
[13] A. Alberti,et al. Estimated prevalence of undiagnosed HCV infected individuals in Italy: A mathematical model by route of transmission and fibrosis progression. , 2021, Epidemics.
[14] Michael V. D’Ambrosio,et al. Amplification-free detection of SARS-CoV-2 with CRISPR-Cas13a and mobile phone microscopy , 2020, Cell.
[15] S. Hutchinson,et al. Reduction in the population prevalence of hepatitis C virus viraemia among people who inject drugs associated with scale-up of direct-acting anti-viral therapy in community drug services: real-world data , 2021 .
[16] D. Hüppe,et al. Versorgungsprobleme von Patienten mit chronischer Hepatitis C während der COVID-19-Pandemie und der Lockdown-Verordnungen , 2020, Zeitschrift für Gastroenterologie.
[17] D. Raben,et al. Impact of the COVID-19 pandemic on testing services for HIV, viral hepatitis and sexually transmitted infections in the WHO European Region, March to August 2020 , 2020, Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.
[18] J. A. Cook,et al. Outcomes following SARS-CoV-2 infection in patients with chronic liver disease: An international registry study , 2020, Journal of Hepatology.
[19] R. Malekzadeh,et al. The case for simplifying and using absolute targets for viral hepatitis elimination goals , 2020, Journal of viral hepatitis.
[20] J. Pawlotsky,et al. EASL recommendations on treatment of hepatitis C - Final update of the series. , 2020, Journal of hepatology.
[21] J. Pawlotsky,et al. Impact of COVID-19 on global HCV elimination efforts , 2020, Journal of Hepatology.
[22] C. James,et al. The impact of COVID-19 on hepatitis elimination , 2020, The Lancet Gastroenterology & Hepatology.
[23] J. Lazarus,et al. Global hepatitis C elimination: an investment framework. , 2020, The lancet. Gastroenterology & hepatology.
[24] J. Lazarus,et al. Progress towards elimination goals for viral hepatitis , 2020, Nature Reviews Gastroenterology & Hepatology.
[25] E. Buscarini,et al. High rates of 30-day mortality in patients with cirrhosis and COVID-19 , 2020, Journal of Hepatology.
[26] Stephen R. Spriggs,et al. CDC Recommendations for Hepatitis C Screening Among Adults — United States, 2020 , 2020, MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports.
[27] I. Waked,et al. Screening and Treatment Program to Eliminate Hepatitis C in Egypt. , 2020, The New England journal of medicine.
[28] A. Gori,et al. Coronavirus disease 2019 and transplantation: A view from the inside , 2020, American Journal of Transplantation.
[29] H. Razavi,et al. Optimization of hepatitis C virus screening strategies by birth cohort in Italy , 2020, Liver international : official journal of the International Association for the Study of the Liver.
[30] G. Dore,et al. Simplified monitoring for hepatitis C virus treatment with glecaprevir plus pibrentasvir, a randomised non-inferiority trial. , 2020, Journal of hepatology.
[31] H. Razavi,et al. Global timing of hepatitis C virus elimination in high‐income countries , 2019, Liver international : official journal of the International Association for the Study of the Liver.
[32] G. Papandreou,et al. Securing sustainable funding for viral hepatitis elimination plans , 2019, Liver international : official journal of the International Association for the Study of the Liver.
[33] N. Luhmann,et al. We know DAAs work, so now what? Simplifying models of care to enhance the hepatitis C cascade , 2019, Journal of internal medicine.
[34] S. Marx,et al. 964 Patient Flow Across Physician Specialties Over the Course of the Hepatitis C Care Cascade: A Real World Analysis From the United States , 2019, American Journal of Gastroenterology.
[35] Rachel Glass,et al. Evaluating the population impact of hepatitis C direct acting antiviral treatment as prevention for people who inject drugs (EPIToPe) – a natural experiment (protocol) , 2019, BMJ Open.
[36] M. Buti,et al. Too many people with viral hepatitis are diagnosed late — with dire consequences , 2019, Nature Reviews Gastroenterology & Hepatology.
[37] J. Lazarus,et al. The Consensus Hepatitis C Cascade of Care: standardized reporting to monitor progress toward elimination. , 2019, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[38] E. Bjornsson,et al. THU-412-Iceland may already have reached the WHO 2030 targets for diagnosis and treatment of hepatitis C virus infection: Results from the treatment as prevention for hepatitis C (Trap HepC) program , 2019, Journal of Hepatology.
[39] J. Ward,et al. Cost Effectiveness of Universal Screening for Hepatitis C Virus Infection in the Era of Direct‐Acting, Pangenotypic Treatment Regimens , 2019, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.
[40] R. Peeling,et al. Accelerating the elimination of viral hepatitis: a Lancet Gastroenterology & Hepatology Commission. , 2019, The lancet. Gastroenterology & hepatology.
[41] Y. Yazdanpanah,et al. Assessing the cost-effectiveness of hepatitis C screening strategies in France. , 2018, Journal of hepatology.
[42] K. Pottie,et al. The Effectiveness and Cost-Effectiveness of Hepatitis C Screening for Migrants in the EU/EEA: A Systematic Review , 2018, International journal of environmental research and public health.
[43] A. Hatzakis,et al. HCV elimination among people who inject drugs. Modelling pre- and post–WHO elimination era , 2018, PloS one.
[44] J. Lazarus,et al. The Micro-Elimination Approach to Eliminating Hepatitis C: Strategic and Operational Considerations , 2018, Seminars in Liver Disease.
[45] M. Pitt,et al. HepFree: Screening migrant patients for viral hepatitis in primary care. A 90,000 patient randomised controlled trial indicates benefits are most obvious in older patients , 2018 .
[46] J. Lazarus,et al. Hepatitis C: The beginning of the end—key elements for successful European and national strategies to eliminate HCV in Europe , 2018, Journal of viral hepatitis.
[47] M. Jauffret-Roustide,et al. Model projections on the impact of HCV treatment in the prevention of HCV transmission among people who inject drugs in Europe. , 2018, Journal of hepatology.
[48] H. Vroling,et al. Public health guidance on prevention and control of blood-borne viruses in prison settings , 2018 .
[49] J. Grebely,et al. Hepatitis C point-of-care diagnostics: in search of a single visit diagnosis , 2017, Expert review of molecular diagnostics.
[50] J. Leung,et al. Global prevalence of injecting drug use and sociodemographic characteristics and prevalence of HIV, HBV, and HCV in people who inject drugs: a multistage systematic review , 2017, The Lancet. Global health.
[51] J. Lazarus,et al. Micro-elimination - A path to global elimination of hepatitis C. , 2017, Journal of hepatology.
[52] M. Buti,et al. Late presentation of chronic viral hepatitis for medical care: a consensus definition , 2017, BMC Medicine.
[53] B. Ringe,et al. Niedrige Seroprävalenz von Hepatitis C bei Flüchtlingen in Deutschland im Jahr 2015 , 2017, Notfall + Rettungsmedizin.
[54] S. Gilbody,et al. Prevalence of HIV, hepatitis B, and hepatitis C in people with severe mental illness: a systematic review and meta-analysis , 2016, The lancet. Psychiatry.
[55] D. Hedrich. Drug-related infectious diseases in Europe , 2015 .
[56] M. Buti,et al. Historical epidemiology of hepatitis C virus (HCV) in selected countries , 2014, Journal of viral hepatitis.
[57] M. Hellard,et al. Are needle and syringe programmes associated with a reduction in HIV transmission among people who inject drugs: a systematic review and meta-analysis. , 2014, International journal of epidemiology.
[58] R. Evans. European Centre for Disease Prevention and Control. , 2014, Nursing standard (Royal College of Nursing (Great Britain) : 1987).
[59] S. Holmberg,et al. Indications for testing among reported cases of HCV infection from enhanced hepatitis surveillance sites in the United States, 2004-2010. , 2013, American journal of public health.
[60] A basis for health policy on aging. Report from the World Health Organization Regional Office for Europe. , 1982, Community medicine.
[61] M. Dumont,et al. European Association for the Study of the Liver , 1971 .